Wide Ranks

FGEN

FibroGen, Inc

0.3890

Top Statistics
Market Cap 39 M Forward PE -1.02 Revenue Growth 14.30 %
Current Ratio 1.41 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -96.84 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6260 Enterprise / Revenue 0.5970 Price To Sales Trailing12 Months 0.2255
Profitability
Profit Margins -96.84 % Operating Margins -21.56 %
Balance Sheet
Total Cash 140 M Total Cash Per Share 1.40 Total Debt 163 M
Total Debt To Equity Current Ratio 1.41 Book Value Per Share -2.07
All Measures
Short Ratio 327.00 % Message Board Id finmb_28484 Fax 415 978 1902
Shares Short Prior Month 4 M City San Francisco Uuid 36a357a0-624b-3e04-a14d-dbb6b1255b8f
Previous Close 0.3876 First Trade Date Epoch Utc 1 B Book Value -2.07
Beta 0.7260 Total Debt 163 M Volume 427845
Fifty Two Week Low 0.1800 Total Cash Per Share 1.40 Total Revenue 173 M
Shares Short Previous Month Date 1 B Target Median Price 0.6000 Audit Risk 10
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -21.56 %
Target Mean Price 0.6000 Net Income To Common -168324000 Short Percent Of Float 0.0507
Implied Shares Outstanding 100 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 140 M
Next Fiscal Year End 1 B Revenue Per Share 1.76 Held Percent Insiders 0.0085
Ebitda Margins -95.41 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 0.3876
Target Low Price 0.6000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.3561
Open 0.3844 Free Cashflow -121833376 State CA
Dividend Yield 0.00 % Return On Assets -0.2655 Time Zone Short Name EST
Board Risk 1 Trailing Eps -1.23 Day Low 0.3779
Address1 409 Illinois Street Shares Outstanding 100 M Compensation Risk 8
Price Hint 4 Target High Price 0.6000 Website https://www.fibrogen.com
52 Week Change -0.2953 Average Volume 1 M Forward Eps -0.6900
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 118.20 %
Is_sp_500 False Regular Market Day High 0.3900 Profit Margins -96.84 %
Fifty Two Week High 2.93 Day High 0.3900 Shares Short 4 M
Regular Market Open 0.3844 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 0.5970 Revenue Growth 14.30 % Shares Percent Shares Out 0.0431
Operating Cashflow -202016000 Currency USD Time Zone Full Name America/New_York
Market Cap 39 M Is_nasdaq_100 False Zip 94158
Quote Type EQUITY Industry Biotechnology Long Name FibroGen, Inc.
Overall Risk 7 Regular Market Day Low 0.3779 Held Percent Institutions 0.5504
Current Price 0.3890 Enterprise To Ebitda -0.6260 Financial Currency USD
Current Ratio 1.41 Gross Margins -34.40 % Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country United States Float Shares 90 M
Two Hundred Day Average 0.9775 Governance Epoch Date 1 B Enterprise Value 103 M
Price To Sales Trailing12 Months 0.2255 Forward PE -1.02 Regular Market Volume 427845
Ebitda -165835008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.